Canagliflozin(kan a gli floe’ zin)
Invokana
PREGNANCY CATEGORY C
Drug Classes
Antidiabetic
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic Actions
Inhibits SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney, resulting in a loss of glucose through the urine and subsequent lowering of blood glucose levels.
Indications
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Contraindications and Cautions
Contraindicated with history of serious hypersensitivity reactions to canagliflozin, severe renal impairment, dialysis, type 1 diabetes, diabetic ketoacidosis.
Use cautiously with hepatic impairment, pregnancy, lactation.
Available Forms
Tablets—100, 300 mg
Dosages
Adults
100 mg/day PO with first meal of the day; may increase to 300 mg/day if needed for glycemic control.
Pediatric patients
Safety and efficacy not established.
Patients with renal impairment
For CrCl of 45–60 mL/min, limit dose to 100 mg/day; for CrCl of less than 45 mL/min, not recommended.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
